Abstract
The incidence of heart failure (HF) is constantly increasing in the Western world. Treatment with statins is well established for the primary and secondary prevention of cardiac events by lowering low-density lipoprotein (LDL) cholesterol levels. There are conflicting reports on the role of LDL cholesterol as an adverse prognostic predictor in patients with advanced HF. The aim of this study was to investigate the association between LDL cholesterol levels and clinical outcomes in 297 patients with severe HF (average New York Heart Association class 2.8). The mean follow-up period was 3.7 years (range 8 months to 11.5 years), and 37% of the patients died during follow-up. The mean time to first hospital admission for HF was 25 +/- 17 months. The study group was divided according to plasma LDL level < or =89, >89 to < or =115, >115 mg/dl. Patients with the highest baseline LDL cholesterol levels had significantly improved outcomes, whereas those with the lowest LDL cholesterol levels had the highest mortality. When analyzed with respect to statin use, it emerged that the negative association between LDL cholesterol level and mortality was present only in the patients with HF who were treated with statins. In conclusion, lower LD...Continue Reading
References
Sep 1, 1990·The Journal of Clinical Investigation·H W HarrisJ H Rapp
May 7, 1998·Cardiology·B M RichartzH Taegtmeyer
Nov 1, 2000·Critical Care Medicine·P FraunbergerD Seidel
Apr 25, 2001·Circulation·A DeswalD L Mann
Aug 15, 2001·Lancet·I J SchatzJ D Curb
Dec 10, 2003·Journal of the American College of Cardiology·Mathias RauchhausStefan D Anker
Jan 30, 2004·JAMA : the Journal of the American Medical Association·Yongmei LiuMichael J Klag
Apr 2, 2005·Zeitschrift für Kardiologie·M BöhmD J van Veldhuisen
Apr 12, 2005·International Journal of Cardiology·U AlehagenU Dahlström
Apr 12, 2005·European Heart Journal·Michael ChristBernhard Maisch
Sep 1, 2005·Circulation·Inder S AnandUNKNOWN Val-HeFT Investigators
Jan 10, 2006·Journal of the American Geriatrics Society·Valérie TikhonoffJan A Staessen
Jul 11, 2006·American Heart Journal·Amresh RainaDaichi Shimbo
Oct 19, 2006·Journal of Cardiac Failure·Kiran K Khush, David D Waters
Oct 20, 2006·International Journal of Cardiology·Henry KrumJay Cohn
Nov 2, 2006·JAMA : the Journal of the American Medical Association·Alan S GoJerry H Gurwitz
Dec 13, 2006·American Heart Journal·Nasim AfsarmaneshGregg C Fonarow
May 12, 2007·The American Journal of Cardiology·Michael DomanskiVandana Sachdev
May 23, 2007·Journal of Cardiac Failure·Masahiko IwaokaKiyotaka Kugiyama
Oct 12, 2007·The New England Journal of Medicine·Ian FordUNKNOWN West of Scotland Coronary Prevention Study Group
Nov 16, 2007·Fundamental & Clinical Pharmacology·Lars GullestadPål Aukrust
Dec 23, 2008·Current Atherosclerosis Reports·Michael Clearfield
Citations
Jan 28, 2014·Zhurnal evoliutsionnoĭ biokhimii i fiziologii·A V Sidorov, M M Fateev
Jan 11, 2011·Annals of the Rheumatic Diseases·Elena MyasoedovaSherine E Gabriel
Nov 28, 2012·World Journal of Cardiology·Gideon CharachJacob George
Jun 24, 2010·Heart Failure Reviews·Petra KleinbongardGerd Heusch
Feb 7, 2012·International Journal of Cardiology·Vecih OduncuCevat Kırma
Feb 16, 2017·Scientific Reports·Grzegorz KopećPiotr Podolec
Mar 16, 2018·Journal of the American Heart Association·Takuya OikawaUNKNOWN CHART‐2 invesigators
Sep 15, 2016·Circulation. Heart Failure·Amanda R VestP Christian Schulze
Jun 16, 2010·Current Opinion in Cardiology·Timo E Strandberg
Mar 5, 2015·Critical Care Medicine·Kai-Hung ChengWen-Ter Lai
Aug 18, 2020·BMJ Open·Liang ZhouChaofu Ke
Oct 15, 2020·Nutrients·Michał CzaplaKatarzyna Łokieć
Jun 3, 2021·Nutrients·Michał CzaplaPiotr Karniej
Jun 11, 2010·Current Opinion in Cardiology